scPharmaceuticals Competitors and Similar CompaniesClear all
scPharmaceuticals's competitors and similar companies include Oxurion and Merus.
 scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. | |
Founding Date | Founding Date 2014 | Founding Date 1991 | Founding Date 2003 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Burlington, US HQ | Locations Leuven, BE HQ Dublin 8, IE | Locations Utrecht, NL HQ Cambridge, US |
Employees | Employees 96256% increase | Employees 785% increase | Employees 260 |
Valuation ($) | Valuation ($) 221.6 m | Valuation ($) 626.1 k | Valuation ($) 3.6 b |
Financial | |||
Revenue (est.) | Revenue (est.) $36.3m (FY, 2024) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $36.1m (FY, 2024) |
Cost of goods | Cost of goods $11.4m (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $25m (FY, 2024) | Gross profit €937k (FY, 2025) | Gross profit $36.1m (FY, 2024) |
Net income | Net income ($85.1m) (FY, 2024) | Net income (€3.7m) (FY, 2025) | Net income ($215.3m) (FY, 2024) |
Funding | |||
Total funding raised | Total funding raised $ 62.5m | Total funding raised $ 3.9m | Total funding raised $ 149.3m |
For sources of this data, please see the company profile
View Company Profiles
Oxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View company